Skip to main content

Table 6 The infectivity of AE-Env clones containing G185, N185 or E185, and the derived mutants

From: Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site

 

Relative infectivity (RLU)a

 

Mutation(s)b

Env clone

Wild-type

N186Q

N197Q

N186Q/N197Q

G185D

G185D/N186Q

E185D/N186Q

G185D/N197Q

N185D/N197Q

E185D/N197Q

G185D/N186Q/N197Q

N185D/N186Q/N197Q

E185D/N186Q/N197Q

21PL2

321

 

109

     

23

    

47CC11

1080

 

670

 

617

  

927

     

50PB2

283

 

296

     

356

    

52PB3

1182

 

362

      

873

   

52PL4

398

 

440

      

535

   

52PL7

161

108

96

168

        

48

60PB2

366

 

404

     

93

    

60PL2

748

 

996

     

908

    

62PL1

297

447

495

300

696

745

 

533

  

78

  

65CC4

88

29

0

0

  

105

      

98CC2

437

 

103

 

579

  

104

     

101PL1

130

149

50

33

       

152

 

102CC2

1056

 

50

      

63

   

104PB4

207

 

112

     

452

    
  1. aInfectivity of Env-recombinant virus was evaluated using U87.CD4.CXCR4 and U87.CD4.CCR5 cells. Relative infectivity of the virus was calculated by comparing it with the luciferase activity of pNL-envCT (pNL4-3)-infected U87.CD4.CXCR4 cells, which was defined as 100 relative light units (RLU).
  2. bSingle or multiple amino acid mutations were introduced into AE-Env-recombinant viruses. Amino acid numbering is based on HXB2 Env gp120.